Onyx Seeks Suitors After Rejecting Amgen’s Bid

July 1 (Bloomberg) -- Onyx Pharmaceuticals, the maker of the cancer drug Nexavar, said it is in contact with other possible acquirers after rejecting an unsolicited $120-a-share cash takeover bid from Amgen Onyx shares surged. Dominic Chu reports on Bloomberg Television's "Market Makers." (Source: Bloomberg)
China's Plunge: What’d You Miss? (Full Show 8/3)
14:09 - Full episode of “What’d You Miss?” Guests: BlackRock’s Peter Fisher and Stern School of Business’ Aswath Damodaran. (Source: Bloomberg)
  • The Impact of China’s Slowdown on BMW Earnings
  • 'Huge Uncertainty' Surrounds Greek Debt Talks: Piccoli
  • Commodities Rout Signaling Structural Shift in Demand